Amneal (India)

In the past two decades, gene editing has transformed genome and epigenome manipulation. CRISPR/Cas technologies enable targeted insertions/deletions, mutagenesis, gene expression modulation, epigenetic edits, mitochondrial changes, and SNP detection for diagnostics and therapies. AI boosts CRISPR precision, efficiency, and cost-effectiveness, optimizing gRNAs via tools like DeepCRISPR, CRISTA, and DeepHF for treating sickle cell anemia and thalassemia. The CRISPR toolkit now supports transgene-free engineering without homology-directed repair, featuring base editing (BE), prime editing (PE), epigenome editing, and CAST for precise DNA modifications and biosensing. AI-genome editing integration powers precision medicine by analyzing patient genomics to pinpoint mutations and biomarkers in cancer, diabetes, and Alzheimer's, enabling personalized diagnostics and therapies. This chapter examines AI's role in enhancing CRISPR-Cas functionalities, benefits, applications, and challenges in medicine.

To understand the distribution of daily doses of IPX203 in a phase 3 clinical study in Parkinson’s disease (PD) patients exposed for at least 12 months, in terms of the doses that patients took most frequently (modal dose), and treatment emergent adverse events (TEAEs) by modal dose.

Potential competing interests: No potential competing interests to declare. Preliminary observations:The article discusses the toxicological evaluation of the aqueous extracts of Clematis hirsuta and Rhamnus prinoides, which are traditionally used in Africa.While clematis is used for inflammation and pain management, the latter is used for various conditions such as respiratory and gastrointestinal tract infections.

An intraarticular, liposphere-based, formulation of Imatinib mesylate for weekly administration was developed. Lipospheres were prepared using double emulsion technique using dierucoyl phosphatidylcholine, 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt), cholesterol, and tricaprylin as lipid phase in dichloromethane in a four-step process. Primary emulsion, formed using a high-pressure homogenizer, was diluted using a secondary aqueous phase in an Inline mixer to form the liposomal dispersion. Nitrogen flushing was done to remove dichloromethane, and the dispersion was finally centrifuged and adjusted for potency. The amount of cholesterol and triglyceride was taken as formulation variables, and speed of homogenization was used as a process variable in the Box-Behnken design while particle size, % drug entrapment, and drug release at the end of 4h and 5days were taken as response variables. Multivariate data analysis grouped the variables in two latent variable sets, one based on the speed and the other on the composition of lipospheres. Multiple linear regression analysis was used to generate mathematical model for each response. Constraints were put on the values of responses, as per the requirements of the final product, and the "freedom to operate" design space was located using an overlay plot. The center point batch sufficed all the set criteria, and Monte Carlo simulations on the factor variables indicated a defect rate of 5%. The center point batch was characterized for viscosity, osmolality, pH, drug release, and lipocrit value. The dispersion was charged in a prefilled syringe and studied for stability. The product was found to be stable at 2-8°C over a period of 6months.

Abstract A practical scalable chemoenzymatic process was developed for the synthesis of ( R )‐3‐(carbamoylmethyl)‐5‐methylhexanoic acid ( 2 ) ( R ‐CMHA) and achieved 98.5% ee and 99% HPLC purity at pilot scale. The systematic statistical design of experimentation (DOE) of esterification, enzymatic desymmetrization and CaCl 2 assisted amidation led to the robust design space.

Onychomycosis is a chronic disorder that is difficult to manage and hard to eradicate with perilous trends to relapse. Due to increased prevalence of HIV, use of immunosuppressant drugs and lifestyle-related factors, population affected with fungal infection of nail (Onychomycosis) happens to increase extensively in last two decades. Modalities available for the treatment of onychomycosis include systemically administered antifungals, mechanical procedures, and topical drug therapy. But the efficacy of the most of approaches to deliver drug at targeted site, i.e., deep-seated infected nail bed is limited due to compact and highly keratinized nail structure. A series of advanced formulation approaches, such as transfersomes, liposomes, nano/micro emulsion, nail lacquers etc., have been attempted to improve the drug penetration into nail plate more efficiently. The manuscript reviews these formulation approaches with their possible mechanisms by which they improve the drug penetration.Comparative analysis of available treatment modalities for onychomycosis has been provided with pros and cons of each alternatives. Additionally, ongoing research about the application of biological materials such as modified cationic antimicrobial peptides (AMPs), plant-derived proteins, and synthetic antimicrobial peptidomimetics have also been explored.

Abstract Novel pyrazolopyrimidine derivatives (IV) (11 examples) are synthesized in high yield via a modified Biginelli multicomponent reaction and screened for their antimycobacterial activities.